Krystal Biotech's - KRYS market analysis on 3rd December 2020

Transaction Date	Recipient	Shares	Type	Price	Value
17th September 2020	Suma Krishnan	1,126	Open or private sale	$47.29	$53,248.31
17th September 2020	Suma Krishnan	7,437	Open or private sale	$46.63	$346,813.34
17th September 2020	Suma Krishnan	10,594	Open or private sale	$46.09	$488,296.53
16th September 2020	Suma Krishnan	9,749	Open or private sale	$46.24	$450,821.06
16th September 2020	Suma Krishnan	5,142	Open or private sale	$46.85	$240,895.50
15th September 2020	Suma Krishnan	14,435	Open or private sale	$46.21	$667,031.25
15th September 2020	Suma Krishnan	1,517	Open or private sale	$47.15	$71,523.21
29th June 2020	Antony A Riley	2,000	Open or private purchase	$14.11	$28,220.00
26th June 2020	Antony A Riley	4,700	Open or private purchase	$14.52	$68,225.20
15th June 2020	Suma Krishnan	8,652	Open or private sale	$42.24	$365,426.74

Krystal Biotech

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Krystal Biotech, Inc. engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform.

Ticker: KRYS

Sector: Healthcare

Industry: Biotechnology

SEC Central Index Key (CIK): 1711279

Employees: 37

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis